🏦 Ayoub v. Spectrum Pharmaceuticals, Inc. Securities Settlement

The consolidated amended complaint alleged that Spectrum made materially false and misleading statements during the class period about the prospects for FDA approval of its cancer treatment drug poziotinib, artificially inflating the price of Spectrum common stock until the truth emerged.

All persons who purchased Spectrum Pharmaceuticals, Inc. common stock (CUSIP 84763A108; formerly traded as Nasdaq: SPPI) between May 12, 2022 and September 22, 2022, inclusive.

Pro rata share of a $7,000,000 cash settlement fund under the Court-approved Plan of Allocation; Lead Plaintiff estimates an average distribution of approximately $0.08 per eligible share before taxes, notice and administration costs, and attorneys' fees

October 12, 2026

October 2, 2026

Ayoub v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10292 (VEC), U.S. District Court for the Southern District of New York (Judge Valerie E. Caproni). Stipulation of Settlement dated June 1, 2026; the proposed $7,000,000 cash settlement fund resolves claims under Sections 10(b) and 20(a) of the Securities Exchange Act. Proof of Claim must be postmarked or submitted online by 11:59 p.m. ET on October 12, 2026; requests for exclusion and objections are due October 30, 2026; the settlement hearing is set for November 20, 2026 at 10:00 a.m. Claims administrator: Strategic Claims Services (Media, PA). Defendants deny all allegations of wrongdoing.